Evidence map›Paper›PMID 41228194›Full record

ArticleCancers2025

Serum Iodine Levels and 8-Year Survival in Patients After Kidney Cancer Diagnosis.

Elżbieta Złowocka-Perłowska, Piotr Baszuk, Adam Kiljańczyk, Wojciech Marciniak, Róża Derkacz, Aleksandra Tołoczko-Grabarek, Andrzej Sikorski, Marcin Słojewski, Adam Gołąb, Artur Lemiński and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elżbieta Złowocka-PerłowskaDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0002-5143-6387
Piotr BaszukDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0002-0676-2597
Adam KiljańczykDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0009-0000-9398-3592
Wojciech MarciniakRead-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.ORCID 0000-0001-7270-0063
Róża DerkaczRead-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland.ORCID 0000-0002-2904-5259
Aleksandra Tołoczko-GrabarekDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.
Andrzej SikorskiDepartment of Urology and Oncological Urology Clinic, Pomeranian Medical University, 71-899 Szczecin, Poland.
Marcin SłojewskiDepartment of Urology and Oncological Urology Clinic, Pomeranian Medical University, 71-899 Szczecin, Poland.
Adam GołąbDepartment of Urology and Oncological Urology Clinic, Pomeranian Medical University, 71-899 Szczecin, Poland.
Artur LemińskiDepartment of Biochemical Research, Pomeranian Medical University, 70-111 Szczecin, Poland.ORCID 0000-0003-1446-2970
Michał SoczawaDepartment of Urology and Oncological Urology Clinic, Pomeranian Medical University, 71-899 Szczecin, Poland.
Magdalena MarciniakDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0001-9070-747X
Rodney J ScottSchool of Biomedical Sciences and Pharmacy, Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW 2305, Australia.ORCID 0000-0001-7724-3404
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0002-3643-2871
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, 70-204 Szczecin, Poland.ORCID 0000-0003-2931-3003

Funding

Pomeranian Medical University FSN-426-08/22
6 · The paper itself

Abstract

BACKGROUND/

objectivesThe aim of this study was to evaluate the association between serum iodine (I) levels and kidney cancer mortality. The role of serum iodine levels in relation to 8-year survival rates in survivors of kidney cancer has not previously been established. In this prospective study, we analyzed 284 consecutive, unselected survivors of kidney cancer and determined their 8-year survival in relation to iodine levels.

methodsMicronutrient levels were measured using inductively coupled plasma mass spectrometry (ICP-MS). Each survivors of kidney cancer was assigned to one of four groups based on the quartile distribution of iodine levels, ranked in ascending order. The multivariable models included covariates such as age at diagnosis, sex, smoking status, type of surgery, histopathological classification and serum levels of selenium, zinc, copper and the zinc-to-copper ratio.

resultsWe observed that survivors of kidney cancer with serum iodine levels in quartiles III and IV had significantly higher all-cause mortality compared to those in quartile II (reference quartile) (HR = 2.83;

conclusionsTo our knowledge, this study is the first investigation of relationship between serum iodine levels and survival of survivors of kidney cancer.

Indexed as

iodinekidney cancersurvival

Identifiers

PMID41228194
PMCPMC12610845

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.